



Thermal degradation products derived from the smoke of *Salvia divinorum* leaves

Zhongze Ma^a, Gang Deng^a, Ronghua Dai^a, Wei Xu^b, Lee-Yuan Liu-Chen^b, David Y. W. Lee^{a,*}

^aBio-Organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, United States

^bDepartment of Pharmacology and Center for Substance Abuse Research, School of Medicine, Temple University, 3420 N. Broad St, Philadelphia, PA 19140, United States

ARTICLE INFO

Article history:

Received 2 April 2010

Revised 9 August 2010

Accepted 10 August 2010

Available online 14 August 2010

Keywords:

Salvia divinorum

Salvinorin A

Smoke

Kappa opioid receptor

ABSTRACT

Smoking of *Salvia divinorum* leaves is the most common method for its psychotropic effects. Eleven thermal degradation products, including a new neoclerodane diterpene derivative, were isolated from the smoke of *S. divinorum* leaves, and their structures were identified by spectroscopic methods. The isolated compounds were evaluated for their binding affinities at the opioid receptors, and salvinorin A is still the most potent kappa opioid receptor agonist.

© 2010 Published by Elsevier Ltd.

Salvia divinorum, a Mexican psychoactive plant, has been used in traditional spiritual ritual for centuries. Its commercial products, leaves and concentrated extracts, are widely available on the internet.^{1,2} Smoking the leaves represents one of the common practices for experiencing the psychotropic effects, including hallucination and mood changes.^{3–5} The concerns of its safety and pharmacological side effects, especially among the adolescence population, have led to a ban on the possession and selling of *S. divinorum* in several U.S. states.⁶ Recently, González et al. reported that smoking the concentrated extract of *Salvia* leaves was the major route of administration among recreational users, and the effects were more potent and intense.⁷ Chemical studies of *S. divinorum* have yielded the structurally related neoclerodane diterpenoids salvinorins A–I, divinorins A–F, salvinicins A and B, and salvidivins A–D.⁸ Among those compounds, salvinorin A (**1**) was identified as a potent and selective kappa opioid receptor (KOPR) agonist and the key ingredient responsible for psychoactive effects.^{9,10} However, the chemical components of the smoke of *S. divinorum* leaves are still unclear. Therefore, in order to understand the biological and pharmacological principles of the smoke of *S. divinorum*, we report herein the isolation and structural elucidation of eleven thermal degradation products including one new compound (**4**) from the smoke of leaves.

The dried leaves (750 g) or concentrated extract (10×, 90 g) of *S. divinorum* was burned and the smoke was collected in a series of cold traps filled with CHCl₃ and H₂O (see Supplementary data). The solutions were evaporated under reduced pressure to obtain

CHCl₃ and H₂O extracts, respectively. Based on the binding results at the opioid receptors, only CHCl₃ extract showed potent binding activities. Subsequently, the CHCl₃ extracts (40 g from leaves and 10 g from concentrated extract) were chromatographed, respectively, on silica gel columns and eluted with *n*-hexane–AcOEt to give sub-fractions, which were subjected to repeated silica gel or C-18 column chromatography to give eleven thermo-degradation products. Salvinorin A (**1**, 0.5 mg, see Fig. 1),¹¹ pyrocoll (10 mg),¹² 3-methyl-indole (8 mg),¹³ indole (5 mg),^{14,15} 2-hydroxypyridine (20 mg),^{16,17} 3-hydroxypyridine (15 mg),¹⁸ 3-hydroxy-2-methylpyridine (10 mg),¹⁹ and β-sitosterol (50 mg)²⁰ were isolated from the CHCl₃ fraction of burned *Salvia* leaves, while salvinorin A (**1**, 53 mg),¹¹ 8-epi-salvinorin A (**2**, 35 mg),²¹ 2-deacetoxy-8-epi-salvinorin A (**3**, 15 mg),²² 1-deacetoxy-8-epi-salvinorin G (**4**, 2 mg), and β-sitosterol (250 mg)²⁰ were obtained from the CHCl₃ fraction of burned *Salvia* extract. The known compounds were identified by comparison with their published data or authentic samples. It should be noted that the isolated nitrogenous compounds have been reported as thermal decomposition products isolated from the smoke of tobacco cigarette.²³

Compound **4** was obtained as a white powder with $[\alpha]_D^{23} -32$ (c 0.16, CHCl₃). Its molecular formula was determined to be C₂₁H₂₄O₆ on the basis of HR ESI-MS at m/z 395.1467 [M+Na]⁺ (calcd 395.1471). The IR spectrum disclosed the absorption bands due to carbonyl groups (1731 and 1693 cm⁻¹). The characteristic ¹H NMR spectrum revealed the presence of two tertiary methyl groups (δ 1.33 and 1.48), an oxygenated methine proton (δ 5.28), and four olefinic protons (δ 6.26, 6.40, 7.42, and 7.47). The ¹³C NMR spectrum of **4** revealed 21 carbon signals, which were ascribed to three methyls (δ 17.9, 23.6, and 52.3), four methylenes

* Corresponding author. Tel.: +1 617 855 2038; fax: +1 617 855 2040.

E-mail address: dlee@mclean.harvard.edu (D.Y.W. Lee).




Figure 1. Neoclerodane diterpene derivatives isolated from the smoke of *S. divinorum* leaves.

(δ 17.7, 29.6, 35.3, and 48.2), seven methines (δ 44.2, 50.7, 69.6, 108.3, 129.4, 139.8, and 143.8), four quaternary carbons (δ 35.4, 38.4, 123.4, and 159.6), and three carbonyl carbons (δ 166.6, 173.5, and 198.9). Comparison of the ^1H and ^{13}C NMR spectra of **4** with those of salvinorin G¹¹ and deacetylsalvinorin G²⁴ suggested that these compounds were structurally similar. According to the ^1H - ^1H COSY, HMQC, and HMBC spectra (Table 1 and Fig. 2), it was confirmed that the oxygen-containing group at C-1 was eliminated. The relative stereochemistry of H-8 in **4** was assigned as α -orientation, based on NOESY cross-peak between H-8 and H-12, and comparison of the ^{13}C NMR chemical shifts at C-8, C-11, C-12, C-13, C-17, and C-20 with those of natural and unnatural salvinorin derivatives.^{22,24} Accordingly, the structure of **4** was determined as 1-deacetoxy-8-epi-salvinorin G.

Among the isolated compounds, we have previously reported that salvinorin A (**1**) has high affinity ($K_i = 1.0 \pm 0.1$ nM), and 8-epi-salvinorin A (**2**) has modest affinity ($K_i = 77 \pm 4$ nM) at the KOPR.²¹ All other compounds were screened for binding affinity at opioid receptors in membranes of CHO cells stably transfected with an opioid receptor (see Supplementary data). At 3 μM , none of the compounds inhibited [^3H]diprenorphine binding to mu, delta, and kappa opioid receptors by more than 50%, indicating that they did not have significant binding affinity. Our findings provide scientific explanation as to why smoking the concentrated extracts




Figure 2. Significant HMBC correlations of **4**.

is more effective than smoking the leaves. Salvinorins **1–4** were found in much higher quantity in the smoke of concentrated extract than those in the smoke of leaves. Total 105 mg of salvinorins **1–4** were isolated from the smoke of 90 g of concentrated extracts, while only 0.5 mg of **1** was isolated from that of 750 g of *Salvia* leaves.

Burning the *Salvia* leaves produced a significant amount of 8-epi-salvinorin derivatives (**2–4**). Previous chemical studies have demonstrated that **1** and its derivatives readily underwent epimerization at C-8 under basic conditions.²⁵ The mechanism of epimerization proposed by Munro et al. involves enolization of the lactone.^{26,27} Further epimerization studies demonstrated that the equilibrium favors the H-8 α epimer over the H-8 β stereochemistry.^{28,29} Because the energy barrier between the chair and boat conformation of δ -lactones is small, the difference between C8-axial and equatorial substituents is minimized.²⁸ Therefore, the thermodynamically favored products of natural salvinorins in the smoke of *S. divinorum* leaves could be 8-epi-salvinorin derivatives.

In summary, eleven thermal degradation products were isolated from the smoke of *S. divinorum* leaves. The major structural changes of neoclerodane diterpenoids include the C-8 epimerization and acetoxy elimination. Biological binding data suggest that salvinorin A (**1**) is still the key ingredient responsible for psychoactive effects.

Acknowledgments

The authors wish to thank Dr. Yongxuan Su, University of California, San Diego for MS measurements. This work was supported by a research grant (R01-DA019688) from NIDA, NIH.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2010.08.033.

Table 1

^1H (300 MHz) and ^{13}C NMR data (75 MHz) for **4** in CDCl_3

No. C	δ_{H}	δ_{C}
1	2.53 (dd, 14.1, 17.4) 2.38 (dd, 3.3, 17.4)	35.3
2		198.9
3	6.26 (s)	129.4
4		159.6
5		38.4
6	2.14 (dt, 12.9, 3.6) 1.64–1.78 (m)	29.6
7	2.28 (dq, 14.4, 2.4) 1.88–2.00 (m)	17.7
8	2.55 (d, 3.3)	44.2
9		35.4
10	1.83 (dd, 3.3, 14.1)	50.7
11	1.90–2.02 (m) 1.64–1.78 (m)	48.2
12	5.28 (d, 12.6)	69.6
13		123.4
14	6.40 (d, 0.9)	108.3
15	7.42 (t, 1.8)	143.8
16	7.47 (d, 0.6)	139.8
17		173.5
18		166.6
19	1.48 (s)	17.9
20	1.33 (s)	23.6
CO_2CH_3	3.79 (s)	52.3

References and notes

1. Siebert, D. J. *J. Ethnopharmacol.* **1994**, *43*, 53–56.
2. Butelman, E. R.; Prisinzano, T. E.; Deng, H.; Rus, S.; Kreek, M. J. *J. Pharmacol. Exp. Ther.* **2009**, *328*, 588–597.
3. Sheffler, D. J.; Roth, B. L. *Trends Pharmacol. Sci.* **2003**, *24*, 107–109.
4. Valdes, L. J., III; Butler, W. M.; Hatfield, G. M.; Paul, A. G.; Koreeda, M. *J. Org. Chem.* **1984**, *49*, 4716–4720.
5. Prisinzano, T. E. *J. Nat. Prod.* **2009**, *72*, 581–587.
6. Kutrzeba, L. M.; Ferreira, D.; Zjawiony, J. K. *J. Nat. Prod.* **2009**, *72*, 1361–1363.
7. González, D.; Riba, J.; Bouso, J. C.; Gómez-Jarabo, G.; Barbanoj, M. *J. Drug Alcohol Depend.* **2006**, *85*, 157–162.
8. Prisinzano, T. E.; Rothman, R. B. *Chem. Rev.* **2008**, *108*, 1732–1743.
9. Ortega, A.; Blount, J. F.; Manchand, P. S. *J. Chem. Soc., Perkin Trans. 1* **1982**, 2505–2508.
10. Roth, B. L.; Baner, K.; Westkaemper, R.; Siebert, D. J.; Rice, K. C.; Steinberg, S.; Ernsberger, P.; Rothman, R. B. *Proc. Natl. Acad. Sci.* **2002**, *99*, 11934–11939.
11. Lee, D. Y. W.; Ma, Z.; Liu-Chen, L.-Y.; Wang, Y.; Chen, Y.; Carlezon, W. A.; Cohen, B. *Bioorg. Med. Chem.* **2005**, *13*, 5635–5639.
12. Dieter, A.; Hamm, A.; Fiedler, H.-P.; Goodfellow, M.; Mueller, W. E. G.; Brun, R.; Beil, W.; Bringmann, G. *J. Antibiot.* **2003**, *56*, 639–646.
13. Jensen, T.; Pedersen, H.; Bang-Andersen, B.; Madsen, R.; Joergensen, M. *Angew. Chem., Int. Ed.* **2008**, *47*, 888–890.
14. Schoenebeck, F.; Murphy, J. A.; Zhou, S.-Z.; Uenoyama, Y.; Miclo, Y.; Tuttle, T. J. *Am. Chem. Soc.* **2007**, *129*, 13368–13369.
15. Kamienska-Trela, K.; Kania, L.; Bechcicka, M.; Kaczmarek, L. *J. Mol. Struct.* **2003**, *661–662*, 209–218.
16. De, S. R.; Ghorai, S. K.; Mal, D. *J. Org. Chem.* **2009**, *74*, 1598–1604.
17. Toganoh, M.; Fujino, K.; Ikeda, S.; Furuta, H. *Tetrahedron Lett.* **2008**, *49*, 1488–1491.
18. Rahman, O.; Kihlberg, T.; Lngstroem, B. *J. Org. Chem.* **2003**, *68*, 3558–3562.
19. Jida, M.; Ollivier, J. *Eur. J. Org. Chem.* **2008**, 4041–4049.
20. Tang, J.; Chen, J.; Tian, J.; Wang, Y.; Wu, F. *Sichuan Daxue Xuebao, Ziran Kexueban* **2002**, *39*, 538–541.
21. Lee, D. Y. W.; Karnati, V. V. R.; He, M.; Liu-Chen, L.-Y.; Kondaveti, L.; Ma, Z.; Wang, Y.; Chen, Y.; Beguin, C.; Carlezon, W. A.; Cohen, B. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3744–3747.
22. Harding, W. W.; Schmidt, M.; Tidgewell, K.; Kannan, P.; Holden, K. G.; Gilmour, B.; Navarro, H.; Rothman, R. B.; Prisinzano, T. E. *J. Nat. Prod.* **2006**, *69*, 107–112.
23. Rodgman, A.; Perfetti, T. A. *The Chemical Components of Tobacco and Tobacco Smoke*; CRS Press, Taylor and Francis Group, 2009.
24. Ma, Z.; Lee, D. Y. W. *Tetrahedron Lett.* **2008**, *49*, 1782–1785.
25. Ma, Z.; Lee, D. Y. W. *Tetrahedron Lett.* **2007**, *48*, 5461–5464.
26. Munro, T. A.; Rizzacasa, M. A.; Roth, B. L.; Toth, B. A.; Yan, F. *J. Med. Chem.* **2005**, *48*, 345–348.
27. Munro, T. A.; Duncan, K. K.; Staples, R. J.; Xu, W.; Liu-Chen, L.-Y.; Beguin, C.; Carlezon, W. A.; Cohen, B. *Beilstein J. Org. Chem.* **2007**, *3*.
28. Lawrence, J. F. I. *Studies Toward the Total Synthesis of Eleutherobin; II. Total Synthesis of Salvinorin A*. Ph.D. Thesis, Harvard University, Cambridge, MA, USA, 2008; pp 175–176.
29. Scheerer, J. R.; Lawrence, J. F.; Wang, G. C.; Evans, D. A. *Am. Chem. Soc.* **2007**, *129*, 8968–8969.